EFFICACY OF GALCANEZUMAB IN PATIENTS WHO FAILED TO RESPOND TO PREVENTIVES PREVIOUSLY: RESULTS FROM EVOLVE-1, EVOLVE-2 AND REGAIN STUDIES

被引：0
|
作者：
Zhang, Q. [1 ]
Ruff, D. D. [1 ]
Pearlman, E. M. [2 ]
Govindan, S. [3 ]
Aurora, S. [4 ]
机构：
[1] Eli Lilly & Co, Stat Neurosci LTC, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Migraine Headache, Indianapolis, IN 46285 USA
[3] Eli Lilly & Co, Med Writing, LCCI Biometr, Bangalore, Karnataka, India
[4] Eli Lilly & Co, Gakanezumab Launch, Indianapolis, IN 46285 USA
来源：
CEPHALALGIA | 2018年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS2018-0
引用
收藏
页码：51 / 52
页数：2
相关论文
共 50 条
  • [1] Efficacy of Galcanezumab in Patients Who Failed to Respond to Preventives Previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN Studies
    Zhang, Q.
    Ruff, D.
    Pearlman, E.
    Govindan, S.
    Aurora, S.
    HEADACHE, 2018, 58 : 165 - 166
  • [2] Efficacy of galcanezumab in patients who failed to respond to preventives previously: results from EVOLVE-1, EVOLVE-2 and REGAIN studies
    Zhang, Q.
    Ruff, D. D.
    Pearlman, E. M.
    Govindan, S.
    Aurora, S. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 298 - 298
  • [3] Efficacy of galcanezumab in patients who failed prior preventive treatments for migraine: results from EVOLVE-1, EVOLVE-2 and REGAIN studies
    Dell'Agnello, Grazia
    Tockhorn-Heidenreich, Antje
    Zhang, Qi
    Ruff, Dustin D.
    Pearlman, Eric M.
    Aurora, Sheena K.
    Ford, Janet H.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [4] EFFECT OF GALCANEZUMAB ON POSSIBLE MENSTRUAL-RELATED MIGRAINE: EXPLORATORY ANALYSES RESULTS FROM EVOLVE-1, EVOLVE-2 AND REGAIN
    Fernandes, M. F. S.
    Detke, H. C.
    Zhang, Q.
    Pavlovic, J. M.
    Aurora, S.
    CEPHALALGIA, 2018, 38 : 97 - 98
  • [5] Effect of galcanezumab on possible menstrual-related migraine: exploratory analyses results from EVOLVE-1, EVOLVE-2 and REGAIN
    Fernandes, Maria S.
    Detke, Holland C.
    Zhang, Qi
    Pavlovic, Jelena M.
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [6] Effect of galcanezumab following double-blind treatment in patients with migraine: results from EVOLVE-1 and EVOLVE-2
    Zhang, Qi
    Morrow, Paula A.
    Stauffer, Virginia L.
    Skljarevski, Vladimir
    Pearlman, Eric M.
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [7] Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies
    Nichols, Russell
    Doty, Erin
    Sacco, Sara
    Ruff, Dustin
    Pearlman, Eric
    Aurora, Sheena K.
    HEADACHE, 2019, 59 (02): : 192 - 204
  • [8] Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase
    Skljarevski, Vladimir
    Stauffer, Virginia L.
    Zhang, Qi
    Detke, Holland C.
    Millen, Brian A.
    Yang, Jyun Yan
    Selzler, Katherine J.
    Conley, Robert
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [9] Benefit-Risk Assessment of Galcanezumab versus Placebo for the Treatment of Episodic and Chronic Migraine: Results from EVOLVE-1, EVOLVE-2, and REGAIN Clinical Trials
    Ruff, Dustin D.
    Tockhorn-Heidenreich, Antje
    Foster, Shonda A.
    Nichols, Russell M.
    Stauffer, Virginia L.
    CEPHALALGIA, 2019, 39 : 219 - 220
  • [10] Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase
    Skljarevski, Vladimir
    Stauffer, Virginia L.
    Zhang, Qi
    Detke, Holland C.
    Millen, Brian A.
    Yang, Jyun Yan
    Selzler, Katherine J.
    Conley, Robert
    Aurora, Sheena K.
    CEPHALALGIA, 2017, 37 : 339 - 340
12345